التفاصيل البيبلوغرافية
| العنوان: |
Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia. |
| المؤلفون: |
Sanz, Jaime1,2,3 (AUTHOR) sanz_jai@gva.es, Moscardó, Federico1 (AUTHOR), Montoro, Juan1 (AUTHOR), Cano, Isabel1 (AUTHOR), Guerreiro, Manuel1 (AUTHOR), Dasí, María A.4 (AUTHOR), Solves, Pilar1,2 (AUTHOR), Lorenzo, Ignacio1,2 (AUTHOR), Gómez-Segui, Inés1,2 (AUTHOR), Montesinos, Pau1,2 (AUTHOR), Mora, Elvira1 (AUTHOR), Arnao, Mario1 (AUTHOR), Sempere, Amparo1,2 (AUTHOR), Jarque, Isidro1,2 (AUTHOR), Carretero, Carlos1 (AUTHOR), Senent, Leonor1,2 (AUTHOR), Vicente, Ana1 (AUTHOR), Andreu, Rafael1 (AUTHOR), Luna, Irene1 (AUTHOR), Balaguer-Roselló, Aitana1 (AUTHOR) |
| المصدر: |
Biology of Blood & Marrow Transplantation. Jan2020, Vol. 26 Issue 1, p83-87. 5p. |
| مصطلحات موضوعية: |
*STEM cell transplantation, *APLASTIC anemia, *BLOOD cells, *GRAFTING (Horticulture), *KARNOFSKY Performance Status, *ALEMTUZUMAB, *GRAFT versus host disease |
| مستخلص: |
• PBSCT from HLA-identical siblings using partial T cell depletion for patients with SAA is safe and associated with a low incidence of acute GVHD and chronic GVHD. • The procedure is effective with high engraftment, low TRM, and high cure rates. We analyzed the outcomes of 26 consecutive patients with acquired severe aplastic anemia (SAA) undergoing peripheral blood stem cell transplantation (PBSCT) with partial ex vivo T cell depletion with a targeted T cell dose from HLA-identical sibling donors. The median patient age was 37 years (range, 3 to 63 years). Four patients with uncontrolled pneumonia at the time of transplantation died, on days +1, +2, +21, and +26. All evaluable patients engrafted, with a median time to neutrophil recovery of 11 days (range, 10 to 14 days) and a median time to platelet recovery of 19 days (range, 8 to 53 days). Two patients had transient grade I acute graft-versus-host disease (GVHD) with skin involvement, but no patients developed grade II-IV acute GVHD. Two patients had mild skin chronic GVHD, and 1 patient had moderate chronic GVHD with ocular involvement. No relapse was observed after a median follow-up of 114 months (range, 4 to 233 months). The overall cumulative incidence of TRM at 10 years was 19%, whereas it was 5% for those with a Karnofsky Performance Status (KPS) score >60 at the time of transplantation. Disease-free survival, overall survival, and GVHD and relapse-free survival at 10 years were 81%, 81%, and 80%, respectively, for all patients and 95%, 95%, and 90%, respectively, for patients with a KPS score >60 at transplantation. Our data indicate that PBSCT with partial ex vivo T cell-depleted targeted cell dose grafts from an HLA-identical sibling donor is a feasible, safe, and effective approach to reduce GVHD and cure patients with SAA. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder